Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients - Full Text View

Purpose

Patients with hip fractures have suffered the most devastating consequence of osteoporosis; and yet, they are rarely if ever tested or treated for the condition, even though they remain at high risk of recurrent fracture.

We hypothesize that, compared with usual care, an allied health professional-run osteoporosis service (case management) will be able to increase testing and treatment of osteoporosis in patients at high risk of fracture.

Condition	Intervention
Osteoporosis Hip Fracture	Behavioral: Allied health professional-run osteoporosis service ("case-management")

MedlinePlus related topics:

Fractures Hip Injuries and Disorders Hip Replacement Osteoporosis

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients

Further study details as provided by University of Alberta:

Primary Outcome Measures:

The proportion of patients taking bisphosphonate therapy within 6 months of hip fracture

Secondary Outcome Measures:

Proportion of patients taking prescription osteoporosis treatment at 6 months and 12 months
Proportion in receipt of a BMD test at 6 months and 12 months
Proportion still adherent to osteoporosis treatments at 6 months and 12 months
Proportion of patients with recurrent fractures at 6 months and 12 months
Cost effectiveness analyses

Estimated Enrollment:	220
Study Start Date:	March 2002

Detailed Description:

Patients with hip fractures have suffered the most devastating consequence of osteoporosis; and yet, they are rarely if ever tested or treated for the condition, even though they remain at high risk of recurrent fracture.

We hypothesize that, compared with usual care, an allied health professional-run osteoporosis service (case management) will be able to increase testing and treatment of osteoporosis in patients at high risk of fracture.

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

hip fracture patient > 50 years of age
able to give consent (or proxy consent available)
lives within health region
no contraindications to bisphosphonate therapy

Exclusion Criteria:

refuses to participate or consent
dementia or delirium without a proxy consent available
nursing home or longterm care
pathologic fracture
chronic glucocorticoid use
already receiving prescription osteoporosis treatment (calcium and vitamin D do not preclude inclusion)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00175175

Locations


Canada, Alberta
	University of Alberta Hospitals
	Edmonton, Alberta, Canada, T6G 2B7

Sponsors and Collaborators

University of Alberta

Alberta Heritage Foundation for Medical Research

Royal Alexandra Hospital

Investigators


Principal Investigator:	Sumit R Majumdar, MD, MPH	University of Alberta

More Information

Publications indexed to this study:

Majumdar SR, Beaupre LA, Harley CH, Hanley DA, Lier DA, Juby AG, Maksymowych WP, Cinats JG, Bell NR, Morrish DW. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med. 2007 Oct 22;167(19):2110-5.

Study ID Numbers:	AHFMR #200100791
First Received:	September 9, 2005
Last Updated:	September 13, 2006
ClinicalTrials.gov Identifier:	NCT00175175
Health Authority:	Canada: Health Canada

Keywords provided by University of Alberta:

osteoporosis treatment

osteoporosis testing

hip fracture

quality improvement

Study placed in the following topic categories:

Hip Fractures

Femoral Fractures

Musculoskeletal Diseases

Fractures, Bone

Wounds and Injuries

Disorders of Environmental Origin

Osteoporosis

Bone Diseases, Metabolic

Leg Injuries

Bone Diseases

Additional relevant MeSH terms:

Hip Injuries

ClinicalTrials.gov processed this record on September 05, 2008

Sponsors and Collaborators:	University of Alberta Alberta Heritage Foundation for Medical Research Royal Alexandra Hospital
Information provided by:	University of Alberta
ClinicalTrials.gov Identifier:	NCT00175175